Article

Pharmacy Tied to Meningitis Outbreak Files for Bankruptcy

The New England Compounding Center, the compounding pharmacy that produced the tainted drugs that killed 39 people and injured more than 600 others, filed for bankruptcy Friday.

The Framingham, Mass., company shut its doors in October after public health officials traced a nationwide outbreak of meningitis to the firm's shipments of tainted vials of methylprednisolone acetate, an injectable drug prescribed by some pain physicians for back ailments.

Read the full story: http://bit.ly/Tjweno

Source: ModernHealthcare.com

Related Videos
Shawn Griffin, MD, sitting for a video interview
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
John Michael O'Brien, PharmD, MPH
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
1 expert in this video
1 expert in this video
Related Content
Fillingoutaformforaclinicaltrial | Image Credit: © KayExam/peopleimages.com-stock.adobe.com
April 30th 2025

Keep Patients at the Center of Clinical Research

Maggie L. Shaw
Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
gene therapy | Image Credit: © RFBSIP - stock.adobe.com
April 30th 2025

Expanding Broader Patient Access to CGTs

Pearl Steinzor
Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
FDA approved. | Image Credit: Pawel - stock.adobe.com
April 30th 2025

FDA Approves Nipocalimab for Generalized Myasthenia Gravis

Christina Mattina
Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing Vivacity-MG3 study.
The complex interplay between RA and metabolic health can have a significant impact on morbidity and mortality and thus deserves attention, authors of a new review argued. | Image credit: 9nong - stock.adobe.com
April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser
Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo